Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study.

[1]  T. Baglin,et al.  Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology , 2012, British journal of haematology.

[2]  C. Frost,et al.  Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects , 2012, British journal of clinical pharmacology.

[3]  E. Nutescu Apixaban: a novel oral inhibitor of factor Xa. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[4]  C. Frost,et al.  A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects , 2012, Thrombosis and Haemostasis.

[5]  S. Laporte,et al.  UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma. , 2012, Journal of pharmaceutical and biomedical analysis.

[6]  Jun Zhu,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[7]  D. Pinto,et al.  Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor , 2011, Journal of Thrombosis and Thrombolysis.

[8]  X. Delavenne,et al.  HPLC MS/MS method for quantification of meprobamate in human plasma: application to 24/7 clinical toxicology. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[9]  T. Leil,et al.  Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose , 2010, Clinical pharmacology and therapeutics.

[10]  W. Humphreys,et al.  In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies , 2010, Drug Metabolism and Disposition.

[11]  P. Wong,et al.  Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro , 2009, Thrombosis and Haemostasis.

[12]  W. Humphreys,et al.  Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans , 2009, Drug Metabolism and Disposition.

[13]  D. Kubitza,et al.  Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases , 2006, Expert opinion on investigational drugs.

[14]  Donald R. Lynch Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[15]  L. Fauchier,et al.  Apixaban after acute coronary syndrome. , 2011, The New England journal of medicine.